Guanze Medical Information Industry (Holding) Co., Ltd. (Guanze Medical) and Funde (Hong Kong) Investment Holdings Co., Limited (Funde HK) have jointly announced a second postponement in sending out the composite document for Funde HK’s mandatory unconditional cash offer for all issued shares of Guanze Medical not already owned or to be acquired by Funde HK and its concert parties.

The parties were previously required to despatch the document by 10 April 2026, following an earlier extension disclosed on 4 March 2026. According to today’s filing, additional time is needed to complete certain sections—most notably the Independent Financial Adviser’s letter—necessitating a new deadline. An application under Rule 8.2 of the Hong Kong Takeovers Code has been submitted, and the Securities and Futures Commission’s Executive has indicated it is minded to approve an extension up to 17 April 2026.

Both companies will issue further announcements once the composite document and accompanying form of acceptance are dispatched or if there are any further timetable adjustments.

The statement reiterates that Guanze Medical’s board—comprising two executive, one non-executive and three independent non-executive directors—accepts responsibility for the accuracy of the company-related information, while Funde HK’s sole director assumes responsibility for the offeror-related information.